Editas Medicine Company Insiders
EDIT Stock | USD 1.37 0.02 1.44% |
Slightly above 84 percent of Editas Medicine's insiders are selling. The analysis of the overall insider sentiment regarding Editas Medicine suggests that a fairly large number of insiders are terrified. Editas Medicine employs about 246 people. The company is managed by 19 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 12.95 employees per reported executive.
James Mullen Chairman Chairman of the Board |
Insider Sentiment 16
Mostly Selling
Selling | Buying |
Latest Trades
2024-12-03 | Gilmore Neil O'neill | Disposed 1618 @ 2.08 | View | ||
2024-09-04 | Gilmore Neil O'neill | Disposed 1555 @ 3.42 | View | ||
2024-07-25 | Linda Burkly | Disposed 11886 @ 5.42 | View | ||
2024-07-19 | Baisong Mei | Disposed 6619 @ 5.21 | View | ||
2024-06-04 | Gilmore Neil O'neill | Disposed 12191 @ 5.5 | View | ||
2024-05-13 | Jessica Hopfield | Acquired 45000 @ 5.64 | View |
Monitoring Editas Medicine's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Editas |
Editas Medicine Management Team Effectiveness
The company has return on total asset (ROA) of (0.3552) % which means that it has lost $0.3552 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.981) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.73 in 2025. Return On Capital Employed is likely to drop to -1 in 2025. Liabilities And Stockholders Equity is likely to gain to about 394.2 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 44.6 M in 2025.Common Stock Shares Outstanding is likely to drop to about 52.7 M in 2025. Net Loss is likely to gain to about (188.5 M) in 2025
Editas Medicine Workforce Comparison
Editas Medicine is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 9,514. Editas Medicine holds roughly 246 in number of employees claiming about 2.59% of equities under Health Care industry.
Editas Medicine Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Editas Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Editas Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Editas Medicine insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bruce Eaton over two weeks ago Acquisition by Bruce Eaton of 16700 shares of Editas Medicine subject to Rule 16b-3 | ||
O'neill Gilmore Neil over a month ago Acquisition by Oneill Gilmore Neil of 130700 shares of Editas Medicine subject to Rule 16b-3 | ||
Bruce Eaton over a month ago Disposition of 1 shares by Bruce Eaton of Editas Medicine at 8.4 subject to Rule 16b-3 | ||
Scadden David over two months ago Acquisition by Scadden David of 25000 shares of Editas Medicine at 9.55 subject to Rule 16b-3 | ||
Mei Baisong over three months ago Acquisition by Mei Baisong of 54000 shares of Editas Medicine at 8.72 subject to Rule 16b-3 | ||
Mei Baisong over three months ago Disposition of 541 shares by Mei Baisong of Editas Medicine at 2.0772 subject to Rule 16b-3 | ||
Hopfield Jessica over three months ago Acquisition by Hopfield Jessica of 45000 shares of Editas Medicine at 5.6415 subject to Rule 16b-3 | ||
Bruce Eaton over three months ago Acquisition by Bruce Eaton of 50000 shares of Editas Medicine at 8.72 subject to Rule 16b-3 |
Editas Medicine Notable Stakeholders
An Editas Medicine stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Editas Medicine often face trade-offs trying to please all of them. Editas Medicine's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Editas Medicine's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Pr Church | CoFounder Member | Profile | |
Gilmore MD | CEO President | Profile | |
Gilmore ONeill | CEO President | Profile | |
James Mullen | Chairman of the Board | Profile | |
CPA CFA | CFO VP | Profile | |
Bruce Eaton | Exec Officer | Profile | |
Cristi Barnett | Corporate Relations | Profile | |
Charlene JD | Executive Counsel | Profile | |
Michelle Robertson | Principal CFO | Profile | |
David Liu | CoFounder Member | Profile | |
Caren Deardorf | Executive Officer | Profile | |
Harry III | VP Operations | Profile | |
Mark Shearman | Ex Officer | Profile | |
Feng Zhang | CoFounder Member | Profile | |
Baisong MD | Executive Officer | Profile | |
Linea Aspesi | Executive Officer | Profile | |
Linda Burkly | Executive Officer | Profile | |
George Church | CoFounder Member | Profile | |
Gregory Whitehead | Executive Officer | Profile |
About Editas Medicine Management Performance
The success or failure of an entity such as Editas Medicine often depends on how effective the management is. Editas Medicine management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Editas management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Editas management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.69) | (0.73) | |
Return On Capital Employed | (0.95) | (1.00) | |
Return On Assets | (0.69) | (0.73) | |
Return On Equity | (1.77) | (1.68) |
Please note, the imprecision that can be found in Editas Medicine's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Editas Medicine. Check Editas Medicine's Beneish M Score to see the likelihood of Editas Medicine's management manipulating its earnings.
Editas Medicine Workforce Analysis
Traditionally, organizations such as Editas Medicine use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Editas Medicine within its industry.Editas Medicine Manpower Efficiency
Return on Editas Medicine Manpower
Revenue Per Employee | 131.4K | |
Revenue Per Executive | 1.7M | |
Net Loss Per Employee | 963.8K | |
Net Loss Per Executive | 12.5M | |
Working Capital Per Employee | 862.2K | |
Working Capital Per Executive | 11.2M |
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.